

**COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

NOTE: This special called meeting will be held virtually via Zoom webinar.

Thursday, September 17, 2020
1:00 P.M. to 4:00 P.M. (Eastern)

Access Information

| Smartphone/Web | Dial-In |
|--|--|
| https://magellanhealth.zoom.us/j/93047561955 Webinar ID: 930 4756 1955 Password: AUXNP0 | +1 312 626 6799 (US Toll) OR +1 646 558 8656 (US Toll) Webinar ID: 930 4756 1955 Password: 465480 |

AGENDA

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
 - a. Approval of Meeting Minutes
- IV. New Business**
 - a. New Products to Market to be reviewed as single products:
 - i. Xepi™ (Antibiotics, Topical)
 - ii. Zeposia® (Multiple Sclerosis Agents)
 - b. New Products to Market to be reviewed along with their respective classes:
 - i. Xcopri™ (Anticonvulsants)
 - ii. Kynmobi™ (Antiparkinson's Agents)
 - iii. Caplyta™ (Antipsychotics)
 - iv. Nexletol™ and Nexlizet™ (Lipotropics, Other)
 - v. Dayvigo™ (Sedative Hypnotics)
- V. Therapeutic Classes with Recommended Changes**
 - a. Alzheimer's Agents
 - b. Anticonvulsants
 - i. Anticonvulsants: First Generation
 - ii. Anticonvulsants: Second Generation (includes new agent Xcopri™)
 - iii. Anticonvulsants: Carbamazepine Derivatives
 - c. Antimigraine Agents, Other (Anti-Migraine: CGRP Inhibitors)
 - d. Antiparkinson's Agents (includes new agent Kynmobi™)
 - e. Antipsychotics
 - i. First-Generation Antipsychotics
 - ii. Second-Generation Antipsychotics (includes new agent Caplyta™)
 - iii. Antipsychotics: Injectable
 - f. Lipotropics, Other (includes new agents Nexletol™ and Nexlizet™)
 - i. Familial Hypercholesterolemia Agents
 - ii. Lipotropics: Bile Acid Sequestrants

- iii. Lipotropics: Cholesterol Absorption Inhibitor
- iv. Lipotropics: Fibrin Acid Derivatives
- v. Lipotropics: Niacin Derivatives
- vi. Lipotropics: Omega-3 Fatty Acids
- vii. Lipotropics: PCSK9s
- g. Neuropathic Pain
- h. PAH Agents, Oral and Inhaled
- i. Sedative Hypnotics (includes new agent Dayvigo™)
- j. Stimulants and Related Agents
 - i. Narcolepsy Agents
 - ii. Stimulants and Related Agents

VI. Consent Agenda

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

| | |
|------------------------------------|---------------------------------|
| Angiotensin Modulator Combinations | Beta-Blockers |
| Angiotensin Modulators | Bladder Relaxant Preparations |
| Antianginal & Anti-ischemic | BPH Treatments |
| Antiarrhythmics, Oral | Calcium Channel Blockers |
| Anticoagulants | Lipotropics, Statins |
| Antidepressants, Other | Movement Disorders |
| Antidepressants, SSRIs | Platelet Aggregation Inhibitors |
| Antidepressants, Tricyclic | Skeletal Muscle Relaxants |
| Antimigraine Agents, Triptans | Smoking Cessation |
| Anxiolytics | |

VII. Adjournment

- a. Schedule of Upcoming Meetings
 - i. **November 19, 2020**
- b. Collection of Travel Vouchers

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

<https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.